Incidental Mutation 'R9794:Ptgds'
ID 734790
Institutional Source Beutler Lab
Gene Symbol Ptgds
Ensembl Gene ENSMUSG00000015090
Gene Name prostaglandin D2 synthase (brain)
Synonyms L-PGDS, PGD2, Ptgs3
MMRRC Submission
Accession Numbers
Essential gene? Probably non essential (E-score: 0.093) question?
Stock # R9794 (G1)
Quality Score 225.009
Status Not validated
Chromosome 2
Chromosomal Location 25356721-25360058 bp(-) (GRCm39)
Type of Mutation missense
DNA Base Change (assembly) C to A at 25359129 bp (GRCm39)
Zygosity Heterozygous
Amino Acid Change Arginine to Leucine at position 42 (R42L)
Ref Sequence ENSEMBL: ENSMUSP00000015234 (fasta)
Gene Model predicted gene model for transcript(s): [ENSMUST00000015234] [ENSMUST00000114251] [ENSMUST00000114259]
AlphaFold O09114
Predicted Effect probably benign
Transcript: ENSMUST00000015234
AA Change: R42L

PolyPhen 2 Score 0.045 (Sensitivity: 0.94; Specificity: 0.83)
SMART Domains Protein: ENSMUSP00000015234
Gene: ENSMUSG00000015090
AA Change: R42L

DomainStartEndE-ValueType
low complexity region 4 18 N/A INTRINSIC
Pfam:Lipocalin 40 184 4.2e-35 PFAM
Predicted Effect probably benign
Transcript: ENSMUST00000114251
AA Change: R42L

PolyPhen 2 Score 0.045 (Sensitivity: 0.94; Specificity: 0.83)
SMART Domains Protein: ENSMUSP00000109889
Gene: ENSMUSG00000015090
AA Change: R42L

DomainStartEndE-ValueType
low complexity region 4 18 N/A INTRINSIC
Pfam:Lipocalin 40 184 4.2e-35 PFAM
Predicted Effect probably benign
Transcript: ENSMUST00000114259
AA Change: R42L

PolyPhen 2 Score 0.045 (Sensitivity: 0.94; Specificity: 0.83)
SMART Domains Protein: ENSMUSP00000109897
Gene: ENSMUSG00000015090
AA Change: R42L

DomainStartEndE-ValueType
low complexity region 4 18 N/A INTRINSIC
Pfam:Lipocalin 40 184 4.2e-35 PFAM
Coding Region Coverage
  • 1x: 99.9%
  • 3x: 99.8%
  • 10x: 99.5%
  • 20x: 99.0%
Validation Efficiency
MGI Phenotype FUNCTION: [Summary is not available for the mouse gene. This summary is for the human ortholog.] The protein encoded by this gene is a glutathione-independent prostaglandin D synthase that catalyzes the conversion of prostaglandin H2 (PGH2) to postaglandin D2 (PGD2). PGD2 functions as a neuromodulator as well as a trophic factor in the central nervous system. PGD2 is also involved in smooth muscle contraction/relaxation and is a potent inhibitor of platelet aggregation. This gene is preferentially expressed in brain. Studies with transgenic mice overexpressing this gene suggest that this gene may be also involved in the regulation of non-rapid eye movement sleep. [provided by RefSeq, Jul 2008]
PHENOTYPE: Mice homozygous for one knock-out allele fail to exhibit PGE2- and bicuculline-induced allodynia and exhibit decreased susceptibility to IgE-induced PCA. Mice homozygous for another knock-out allele show normal induction of muscle injury after reperfusion of ischemic skeletal muscle. [provided by MGI curators]
Allele List at MGI
Other mutations in this stock
Total: 70 list
GeneRefVarChr/LocMutationPredicted EffectZygosity
9930012K11Rik T A 14: 70,395,038 (GRCm39) I39L possibly damaging Het
Acacb T C 5: 114,387,578 (GRCm39) V2415A probably benign Het
Adgrg6 C A 10: 14,314,196 (GRCm39) G669C probably damaging Het
Ahcyl A G 16: 45,974,342 (GRCm39) V345A probably benign Het
Arhgdib A G 6: 136,906,608 (GRCm39) probably null Het
Arhgef18 G A 8: 3,501,634 (GRCm39) V643I probably benign Het
Aspm T A 1: 139,406,480 (GRCm39) I1789N probably damaging Het
Atm C T 9: 53,429,867 (GRCm39) V390I probably benign Het
AW554918 A G 18: 25,337,031 (GRCm39) E148G probably damaging Het
Bmal2 T A 6: 146,734,033 (GRCm39) D543E probably benign Het
Camk2a T C 18: 61,097,031 (GRCm39) V327A probably benign Het
Celsr3 T C 9: 108,728,502 (GRCm39) V3302A probably benign Het
Ces2a G A 8: 105,467,896 (GRCm39) V509M probably benign Het
Cpa5 T C 6: 30,625,920 (GRCm39) probably null Het
Cplx3 A T 9: 57,509,522 (GRCm39) *159R probably null Het
Cyp2b23 A T 7: 26,381,121 (GRCm39) Y79N probably benign Het
Dapk1 A G 13: 60,909,082 (GRCm39) T1232A probably damaging Het
Dsg3 A T 18: 20,673,154 (GRCm39) T942S probably benign Het
Efnb3 G A 11: 69,448,232 (GRCm39) P70L probably damaging Het
Eln G T 5: 134,751,352 (GRCm39) Y280* probably null Het
Epha8 G T 4: 136,666,035 (GRCm39) H374N probably benign Het
Erbin A T 13: 103,971,359 (GRCm39) D752E probably benign Het
Fam149a A G 8: 45,834,449 (GRCm39) S117P possibly damaging Het
Fchsd2 G A 7: 100,893,410 (GRCm39) C304Y probably benign Het
Galnt6 C A 15: 100,595,859 (GRCm39) V390L probably damaging Het
Grk3 T C 5: 113,121,448 (GRCm39) probably null Het
Il17rc A T 6: 113,453,726 (GRCm39) T237S probably benign Het
Inpp5b A G 4: 124,687,174 (GRCm39) D800G probably damaging Het
Itga11 A G 9: 62,662,868 (GRCm39) N528S probably benign Het
Kif19b T A 5: 140,448,070 (GRCm39) probably null Het
Lancl2 T A 6: 57,714,708 (GRCm39) F442L probably benign Het
Ldah G T 12: 8,318,430 (GRCm39) A180S possibly damaging Het
Lingo1 T C 9: 56,528,592 (GRCm39) E5G probably benign Het
Lingo3 T C 10: 80,670,707 (GRCm39) I408V possibly damaging Het
Liph A T 16: 21,774,862 (GRCm39) L445Q probably damaging Het
Lonrf1 A G 8: 36,703,235 (GRCm39) Y314H probably damaging Het
Lrit3 A T 3: 129,594,073 (GRCm39) L168Q probably damaging Het
Mideas T A 12: 84,220,576 (GRCm39) Q126L probably damaging Het
Mylk4 G T 13: 32,899,950 (GRCm39) T312K probably damaging Het
Myzap A T 9: 71,487,082 (GRCm39) M15K probably benign Het
Ngf G A 3: 102,428,132 (GRCm39) V298M probably damaging Het
Nlrp9a A G 7: 26,264,302 (GRCm39) I741V probably benign Het
Nrxn2 T C 19: 6,567,064 (GRCm39) V1313A possibly damaging Het
Nuf2 C T 1: 169,334,954 (GRCm39) probably null Het
Or13a27 G A 7: 139,925,483 (GRCm39) Q140* probably null Het
Or5m8 A G 2: 85,822,464 (GRCm39) Y101C probably benign Het
Pcdh17 C T 14: 84,770,350 (GRCm39) R943* probably null Het
Phykpl A T 11: 51,489,212 (GRCm39) H346L probably benign Het
Plk4 C A 3: 40,759,535 (GRCm39) L144I probably damaging Het
Pole C A 5: 110,466,201 (GRCm39) P1301Q probably benign Het
Prkch T A 12: 73,744,744 (GRCm39) N252K possibly damaging Het
Psen2 A T 1: 180,068,294 (GRCm39) probably null Het
Ptprz1 A G 6: 23,000,204 (GRCm39) T765A probably benign Het
Rab6b T C 9: 103,041,061 (GRCm39) F152L possibly damaging Het
Rbm12b2 T A 4: 12,095,335 (GRCm39) F731L probably damaging Het
Resf1 T A 6: 149,228,239 (GRCm39) Y428* probably null Het
Rnf32 T C 5: 29,429,125 (GRCm39) I234T probably damaging Het
Scart2 G A 7: 139,874,716 (GRCm39) G398D probably damaging Het
Scn8a T A 15: 100,933,332 (GRCm39) I1512N probably benign Het
Senp6 T A 9: 79,999,590 (GRCm39) D81E probably benign Het
Slc26a7 T G 4: 14,590,416 (GRCm39) N125T possibly damaging Het
Sptlc1 A T 13: 53,512,803 (GRCm39) I185N possibly damaging Het
Syne2 C A 12: 76,047,617 (GRCm39) H4013N probably benign Het
Tbc1d9b T C 11: 50,062,005 (GRCm39) V1171A probably benign Het
Tmem63b T C 17: 45,977,252 (GRCm39) N417S probably benign Het
Ttn A G 2: 76,706,193 (GRCm39) V9176A unknown Het
Vmn1r210 T C 13: 23,011,432 (GRCm39) I285V probably damaging Het
Wbp11 C T 6: 136,795,021 (GRCm39) V308I possibly damaging Het
Wnk2 A C 13: 49,229,674 (GRCm39) V950G probably benign Het
Zfp110 A G 7: 12,578,521 (GRCm39) N144S probably benign Het
Other mutations in Ptgds
AlleleSourceChrCoordTypePredicted EffectPPH Score
IGL02164:Ptgds APN 2 25,359,124 (GRCm39) missense probably damaging 0.99
IGL03035:Ptgds APN 2 25,359,622 (GRCm39) missense probably benign 0.06
IGL03036:Ptgds APN 2 25,359,622 (GRCm39) missense probably benign 0.06
IGL03117:Ptgds APN 2 25,359,622 (GRCm39) missense probably benign 0.06
IGL03352:Ptgds APN 2 25,359,622 (GRCm39) missense probably benign 0.06
IGL03354:Ptgds APN 2 25,359,622 (GRCm39) missense probably benign 0.06
R0780:Ptgds UTSW 2 25,358,104 (GRCm39) missense possibly damaging 0.90
R0885:Ptgds UTSW 2 25,357,357 (GRCm39) missense possibly damaging 0.80
R4820:Ptgds UTSW 2 25,359,058 (GRCm39) missense probably benign 0.02
R7000:Ptgds UTSW 2 25,357,828 (GRCm39) critical splice donor site probably null
R7522:Ptgds UTSW 2 25,357,920 (GRCm39) missense probably benign 0.38
R8401:Ptgds UTSW 2 25,359,669 (GRCm39) missense unknown
Predicted Primers PCR Primer
(F):5'- TTGAAGTAAGGGACCAAGCCC -3'
(R):5'- TCAACACCCTGGGGAAAGAG -3'

Sequencing Primer
(F):5'- CCAGGATGTCTCCCAGAATTTG -3'
(R):5'- GCTACCCACTCCTCCATGGG -3'
Posted On 2022-11-14